Phase III PEMPHIX study shows Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris

Stacey Gandler
Brand Nourishment

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Liz Kane
Impactful Strategy